Despite its benefits, ERT faces several challenges. One major issue is the immune response to the administered enzyme, which can reduce its efficacy and cause adverse effects. Additionally, the intravenous delivery of enzymes may not effectively target certain tissues, such as the central nervous system, due to the blood-brain barrier. Manufacturing and cost are also significant considerations, as producing recombinant enzymes can be expensive.
